Zepbound vs Wegovy: Which GLP-1 Is Better for Weight Loss?

Two of the most talked-about weight loss medications on the market right now are Zepbound (tirzepatide) and Wegovy (semaglutide). Both are FDA-approved for chronic weight management, both work by mimicking gut hormones, and both have impressive clinical trial results. But they work differently, cost differently, and suit different people in different ways. If you’re trying to decide between the two – or just trying to understand what your options are – this breakdown will help.

How Each Medication Works

Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating. It signals your brain that you’re full, slows digestion, and reduces appetite. Wegovy mimics this hormone at higher doses than Ozempic (which uses the same drug but is approved for type 2 diabetes).

Zepbound contains tirzepatide, which takes things a step further. It’s a dual agonist – it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone involved in metabolism and fat storage. By targeting two pathways instead of one, tirzepatide may produce stronger effects on appetite and weight loss in many people.

Weight Loss Results: How Do They Compare?

Both medications have shown substantial results in clinical trials, but the numbers do favor Zepbound:

• Wegovy (semaglutide): In the STEP 1 trial, participants lost an average of about 15% of their body weight over 68 weeks.
• Zepbound (tirzepatide): In the SURMOUNT-1 trial, participants on the highest dose lost an average of about 20.9% of their body weight over 72 weeks.

That difference is meaningful. For a 250-pound person, 15% is 37.5 pounds. At 20.9%, that’s over 52 pounds. However, it’s important to note that these trials weren’t head-to-head comparisons – they used different study populations and protocols. Real-world results vary significantly from person to person.

Some people respond better to semaglutide. Others see better results with tirzepatide. There’s no guaranteed outcome with either drug, and individual factors like metabolism, diet, activity level, and adherence matter enormously.

Side Effects: What to Expect

The side effect profiles of Zepbound and Wegovy are similar, since both slow gastric emptying and affect the gut-brain axis. The most common issues include:

• Nausea (especially early on)
• Vomiting
• Diarrhea or constipation
• Stomach pain or bloating
• Fatigue

Both medications use a slow dose-escalation schedule to minimize side effects as your body adjusts. Some users report that tirzepatide causes slightly more gastrointestinal symptoms at higher doses, while others find it more tolerable than semaglutide. Your experience will likely be unique.

Both carry the same FDA black box warning about a potential (though rare) risk of thyroid C-cell tumors seen in animal studies. Neither should be used if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Cost and Insurance Coverage

Cost is a major real-world factor, and neither drug is cheap without coverage:

• Wegovy: List price around ,349/month. Novo Nordisk offers a savings card that can reduce cost to as low as /month for eligible commercially insured patients, and /month for those without insurance (with income requirements).
• Zepbound: List price around ,059/month. Eli Lilly offers a savings card reducing cost to /month for eligible uninsured patients, or as low as /month with commercial insurance.

Zepbound currently has a slight edge in sticker price, and Lilly has been more aggressive with discount programs. However, insurance coverage varies. Some plans cover one but not the other. Always check your specific formulary before deciding based on cost alone.

Compounded versions of both semaglutide and tirzepatide have been widely available through telehealth providers, often at significantly lower prices. However, FDA restrictions on compounding have been evolving, so availability may change.

Which One Should You Choose?

There’s no universal answer – it depends on your situation. Here’s a simple framework:

• Choose Wegovy if: You or your doctor prefer a longer track record (semaglutide has been studied longer), if Wegovy is better covered by your insurance, or if you’ve already had success with Ozempic and want to stay in the same drug family.
• Choose Zepbound if: You want the medication with the highest average weight loss in trials, if you also have type 2 diabetes (tirzepatide was originally approved as Mounjaro for diabetes), or if the cost savings make it more accessible for you.

Many doctors are now starting with Zepbound for weight loss patients given its dual-action mechanism and strong trial data – but Wegovy remains an excellent option with a solid safety record.

The Bottom Line

Both Zepbound and Wegovy are highly effective GLP-1-based medications that can produce significant, sustained weight loss when combined with lifestyle changes. On average, tirzepatide (Zepbound) shows slightly greater weight loss in clinical trials, but both are transformative options compared to what was available just a few years ago.

Work with your healthcare provider to weigh your medical history, insurance coverage, cost, and personal preferences. The best medication is the one you can afford, tolerate, and stick with long-term. Either choice puts you in the category of using some of the most effective weight management tools in medical history.